ENEkaterina Igorevna Nesterkina

Ekaterina Igorevna Nesterkina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ekaterina Igorevna Nesterkina has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Review of the Certification Procedure for Qualified Persons of Manufacturers of Medicines for Human Use in Russia

    by Zh. I. Aladysheva, N. V. Pyatigorskaya, V. V. Beregovykh, G. E. Brkich, A. P. Meshkovskiy, M. M. Marshalova, V. V. Belyaev, N. S. Nikolenko, E. I. Nesterkina, A. A. Kamaletdinova, et al.

    Scientific relevance. In December 2020, the Russian Federation adopted the Eurasian Economic Union (EAEU) requirements. This has significantly changed the certification procedure for qualified persons (QPs) of manufacturers of medicinal products for human use in the Russian Federation. To accommodate these changes, the Russian regulatory framework needs further improvement.Aim. This study aimed to review the changes made to the mechanism of state regulation of medicines and to evaluate the impact on the pharmaceutical industry two years after the adoption of the current QP certification procedure.Discussion. This review compares two QP certification procedures established by Order No. 7n of the Ministry of Health of the Russian Federation dated 12 January 2021. The first is an abbreviated one for QPs certified under the previous procedure, and the second is an initial one for QPs being certified for the first time, having an expired certificate, or wishing to extend their professional qualification profiles. The article illustrates common mistakes made by certification applicants when preparing their documents. Furthermore, the authors describe the most prevalent knowledge gaps identified by testing. The abbreviated certification procedure ensured a sufficiently smooth transition to the EAEU requirements. For example, by 1 February 2023, 506 QPs were recertified for the next five-year period according to this procedure. This accounts for slightly more than half of all QPs certified in the Russian Federation according to the previous requirements. The total number of QPs certified according to the EAEU requirements in Russia in 2021–2022 is approximately 1.5 times higher than the number of QPs certified during the same period in 2014–2015.Conclusions. The updated procedure for QP certification has noticeably changed the occupational group of QPs formed in the Russian Federation in the last decade. The implementation of the new QP certification procedure has revealed several procedural issues that require additional explanation and clarification by the Ministry of Health of the Russian Federation.

  • Polymorph screening and study of the structure of crystalline forms of phenyltetrahydroquinolinedione derivative with TRPA1-antagonistic activity

    by Natalia Valeryevna Pyatigorskaya, Natalia Sergeevna Nikolenko, Aleksei Dmitrievich Kravchenko, Ekaterina Igorevna Nesterkina

    Введение. 7-(2-хлорофенил)-4-(4-метил-1,3-тиазол-5-ил)-4,6,7,8-тетрагидрохинолин-2,5(1Н,3Н)-дион является новым селективным антагонистом рецепторов TRPA1, который может стать перспективным анальгетическим и противовоспалительным средством нового поколения. Для разработки твердой лекарственной формы изучаемого вещества необходимо определить его характеристики, способные влиять на критические показатели качества готового продукта. К таким параметрам относится полиморфная модификация действующего вещества. Цель исследования. Целью данной работы являлся полиморфный скрининг производного фенилтетрагидрохинолиндиона и изучение строения полученных кристаллических модификаций с применением дифракционных методов анализа. Материал и методы. Порошковая рентгеновская дифракция была проведена на дифрактометре Bruker D8 Discover, оборудованном никелевым фильтром, а также позиционно-чувствительным детектором. Расчеты проведены с помощью программных обеспечений DIFFRAC.SUITE EVA и TOPAS 4.2. Съемка осуществлялась в геометрии Брэгга-Брентано, в режиме отражения. Монокристаллы полиморфных модификаций были получены при перекристаллизации изучаемого вещества из различных органических растворителей и их смесей. Рентгеноструктурный анализ был выполнен на монокристальном рентгеновском дифрактометре Xcalibur-3. Монокристальные структуры расшифрованы прямым методом по комплексу программ SHELXTL. Результаты. Результаты порошковой рентгеновской дифракции показали наличие нескольких кристаллических фаз в нативном образце АФС, однако они не позволили идентифицировать конкретные полиморфы. В результате полиморфного скрининга из различных растворителей было получено несколько монокристаллов, пригодных для рентгеноструктурного анализа. Оценка полученных образцов не показала различий в растворимости полиморфов. Было установлено, что из этанола кристаллизуется ромбическая модификация I, а из метанола, изопропанола, ацетона, смесей ацетон/ацетонитрил или ТГФ/ацетонитрил - триклинная модификация II. Были описаны различия в молекулярном строении полученных полиморфов и их упаковки в кристаллах. Заключение. Полученные и охарактеризованные полиморфы АФС могут быть оценены с целью выбора конкретной кристаллической модификации для дальнейшей разработки твердой лекарственной формы на ее...

  • Open Access

    ACTUAL PROBLEMS OF PROFESSIONAL AND PERSONAL DEVELOPMENT QUALIFIED PERSONS RESPONSIBLE FOR QUALITY OF MEDICINAL PRODUCTS FOR HUMAN USE

    by Zh. I. Aladysheva, N. V. Pyatigorskaya, V. V. Belyaev, N. S. Nikolenko, E. I. Nesterkina, S. A. Loseva

    The aim of the study is to investigate topical problems of the professional and personal development of qualified persons responsible for quality of medicinal products for human use.Materials and methods. In the period from April 6 to May 10, 2020, an online survey of leading employees in the field of quality assurance of Russian manufacturers was conducted. 176 people took part in the survey; the return of questionnaires was about 17.9%.Results. From the standpoint of D. Super’s theory of professional development, the largest number of respondents was at the maintenance stage, holding their achieved positions (53.2%). All respondents, regardless of age, were motivated for professional development. Most often qualified persons had chemical engineering (27.3%) and pharmaceutical education (22.2%). Most of them had a working experience in 1–2 divisions of the enterprise, and combined the functions of qualified persons with managerial positions (74.5% and 71.9%, respectively). The majority of the qualified persons (86.4%) indicated the sufficiency of the available knowledge and the lack of knowledge on certain issues. Knowledge and skills in the quality risk management, specific GMP issues and statistical methods (59.0%, 49.2 and 44.2%, respectively); communication and interpersonal skills and, in particular, stress management, emotion management and the art of negotiation (49.4%, 41.3% and 40.9%, respectively), were most popular. About 36% of respondents notified the need for the digital economy competencies, while only 5.1% notified the presence of an electronic batch production record at the enterprise. Finally, only half of the respondents (50.5%) had a formal training plan for qualified persons.Conclusion. This pilot study revealed the need for the revision of the Exemplary Additional Professional Training Program for Qualified Persons and the professional standard, the urgent need for the regulatory body to develop a scheme and principles for the continuous professional development of qualified persons, and showed the direction of further research in this area.


  • Open Access

    Procedure for Reviewing Pharmaceutical Inspections in the Eurasian Economic Union (Review)

    by A. P. Meshkovskiy, V. V. Beregovykh, V. N. Shestakov, N. V. Pyatigorskaya, Zh. I. Aladysheva, N. S. Nikolenko, A. M. Pyatigorskiy, E. I. Nesterkina

    Introduction. The article discusses significant changes in the procedure for pharmaceutical inspection of drug manufacturers for compliance with the requirements of the rules of good manufacturing practice (GMP) of the Eurasian Economic Union (EAEU), related to restrictions due to the COVID-19 pandemic.Text. The article presents the main international guidelines describing the remote conduct of pharmaceutical inspections, which is the basis for further updating the relevant procedures in the law of the EAEU. An overview of the foreign practice of pharmaceutical inspection during the pandemic is given. In addition, the changes in the Russian regulatory approaches to control and supervision in the Russian legislation are presented.Conclusion. These data give an idea that, with considering the above, there is a need for further convergence of the requirements, the practice of conducting pharmaceutical inspections for compliance with the requirements of GMP Rules in order to harmonize the norms between Russian regulatory documents, the norms of the EAEU law and international standards. This requires the development of a dialogue with the participation of stakeholders.